Trial Profile
A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2022
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms QUADRA
- Sponsors GlaxoSmithKline; GSK; TESARO
- 24 Sep 2021 Status changed from active, no longer recruiting to completed.
- 03 Sep 2020 Planned End Date changed from 30 Mar 2022 to 21 Sep 2021.
- 25 Mar 2020 Planned End Date changed from 1 Dec 2019 to 30 Mar 2022.